Stifel Nicolaus analyst Daniel Arias maintained a Buy rating on Codexis (CDXS – Research Report) today and set a price target of $5.00. The company’s shares closed yesterday at $3.14.
According to TipRanks, Arias is an analyst with an average return of -9.8% and a 37.96% success rate. Arias covers the Healthcare sector, focusing on stocks such as 10x Genomics, Danaher, and Illumina.
In addition to Stifel Nicolaus, Codexis also received a Buy from Craig-Hallum’s Matt Hewitt in a report issued yesterday. However, today, TD Cowen assigned a Hold rating to Codexis (NASDAQ: CDXS).
CDXS market cap is currently $222.7M and has a P/E ratio of -2.87.
Based on the recent corporate insider activity of 18 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of CDXS in relation to earlier this year. Last month, Opaleye Management Inc., a Major Shareholder at CDXS bought 25,000.00 shares for a total of $72,500.00.
TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.
Codexis (CDXS) Company Description:
Codexis, Inc. engages in the discovery, development, and sale of proteins. The company offers enzyme optimization services and developing biocatalyst products. The firm operates through the following segments: Performance Enzymes and Novel Biotherapeutics. Its technologies accelerate the development of manufacturing processes for active pharmaceutical ingredients fine chemicals, agrochemicals, food ingredients, detergents and biofuels. The company was founded in January 2002 and is headquartered in Redwood City, CA.
